Wang Hong-Liang, Yu Kai-Jiang
Hong-Liang Wang, Department of Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China.
World J Gastroenterol. 2015 May 28;21(20):6304-9. doi: 10.3748/wjg.v21.i20.6304.
To evaluate the efficacy of sequential blood purification therapy in the treatment of critical patients with hyperlipidemic severe acute pancreatitis.
Thirty-one intensive care unit (ICU) patients with hyperlipidemic severe acute pancreatitis treated at the Second Affiliated Hospital of Harbin Medical University were divided into either a study group (n = 15; July 1, 2012 to June 30, 2014) or a control group (n = 16; July 1, 2010 to June 30, 2012) based on the implementation of sequential blood purification therapy. The control group received continuous venous-venous hemofiltration (CVVH) on the basis of conventional treatments, and the therapeutic dose of CVVH was 30 mL/kg per hour. The study group received sequential plasma exchange and CVVH on the basis of conventional treatments. The anticoagulation regimen of CVVH is the regional citrate anticoagulation. Mortality rate on day 28, rates of systemic and local complications, duration of ICU, and time to target serum lipid level, as well as physiologic and laboratory indices were compared between the two groups.
The mortality rate on day 28 was significantly lower in the study group than in the control group (13.33% vs 37.50%; P < 0.05). The duration of ICU stay was significantly shorter in the study group than in the control group (7.4 ± 1.35 d vs 9.19 ± 2.99 d, P < 0.05). The time to target serum lipid level was significantly shorter in the study group than in the control group (3.47 ± 0.52 d vs 7.90 ± 1.14 d, P < 0.01). There were no significant differences in the rates of systemic complications and local complications between the two groups (60% vs 50% and 80% vs 81%, respectively). In the comparisons of physiologic and laboratory indices, serum albumin and C-reactive protein were significantly better in the study group than in the control group after treatment (37.8 ± 4.6 g/L vs 38.9 ± 5.7 g/L, and 20.5 ± 6.4 mg/L vs 28.5 ± 7.1 mg/L, respectively, both P < 0.05). With the exception of plateletcrit, no other indices showed significant differences between the two groups.
Sequential blood purification therapy is effective in the treatment of ICU patients with hyperlipidemic severe acute pancreatitis and can improve patient prognosis.
评估序贯血液净化疗法治疗高脂血症性重症急性胰腺炎危重症患者的疗效。
将哈尔滨医科大学附属第二医院收治的31例高脂血症性重症急性胰腺炎重症监护病房(ICU)患者,根据序贯血液净化疗法的实施情况分为研究组(n = 15;2012年7月1日至2014年6月30日)和对照组(n = 16;2010年7月1日至2012年6月30日)。对照组在常规治疗基础上接受持续静脉-静脉血液滤过(CVVH),CVVH治疗剂量为每小时30 mL/kg。研究组在常规治疗基础上接受序贯血浆置换和CVVH。CVVH的抗凝方案为局部枸橼酸抗凝。比较两组患者28天死亡率、全身和局部并发症发生率、ICU住院时间、血脂达标时间以及生理和实验室指标。
研究组28天死亡率显著低于对照组(13.33%对37.50%;P < 0.05)。研究组ICU住院时间显著短于对照组(7.4 ± 1.35天对9.19 ± 2.99天,P < 0.05)。研究组血脂达标时间显著短于对照组(3.47 ± 0.52天对7.90 ± 1.14天,P < 0.01)。两组全身并发症和局部并发症发生率无显著差异(分别为60%对50%和80%对81%)。在生理和实验室指标比较中,治疗后研究组血清白蛋白和C反应蛋白显著优于对照组(分别为37.8 ± 4.6 g/L对38.9 ± 5.7 g/L,以及20.5 ± 6.4 mg/L对28.5 ± 7.1 mg/L,均P < 0.05)。除血小板压积外,两组其他指标无显著差异。
序贯血液净化疗法治疗高脂血症性重症急性胰腺炎ICU患者有效,可改善患者预后。